	US 11,913,078 B2
	Method for breast cancer recurrence prediction under endocrine treatment
Mareike Dartmann, Cologne (DE); Inke Sabine Feder, Cologne (DE); Mathias Gehrmann, Cologne (DE); Guido Hennig, Cologne (DE); Karsten Weber, Cologne (DE); Christian Von Torne, Cologne (DE); Ralf Kronenwett, Colgone (DE); and Christoph Petry, Colgone (DE)
Assigned to MYRIAD INTERNATIONAL GMBH, Cologne (DE)
Filed by MYRIAD INTERNATIONAL GMBH, Cologne (DE)
Filed on Oct. 27, 2020, as Appl. No. 17/081,924.
Application 17/081,924 is a continuation of application No. 16/746,334, filed on Jan. 17, 2020, granted, now 10,851,427.
Application 16/746,334 is a continuation of application No. 15/234,828, filed on Aug. 11, 2016, granted, now 10,577,661, issued on Mar. 3, 2020.
Application 15/234,828 is a continuation of application No. 13/638,360, abandoned, previously published as PCT/EP2011/054855, filed on Mar. 29, 2011.
Claims priority of application No. 10158561 (EP), filed on Mar. 31, 2010.
Prior Publication US 2021/0123107 A1, Apr. 29, 2021
Int. Cl. C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)]

19 Claims

1. A method for treating a patient having an estrogen receptor positive and HER2 negative breast tumor, the method comprising:

determining whether the patient will benefit from cytotoxic chemotherapy by:

(1) determining in a sample from the tumor the RNA expression level values of a set of marker genes, the set of marker genes comprising AURKA and at least two of the following genes: BIRC5, PVALB, NMU, STC2, RBBP8, PTGER3, CXCL12, CDH1, and PIP;

(2) combining the expression level values determined in step (1) to yield a test combined score; and

administering a treatment regimen comprising a cytotoxic chemotherapy to the patient if the test combined score exceeds a reference combined score, or

administering a treatment regimen comprising a non-cytotoxic therapy to the patient if the test combined score does not exceed the reference combined score.